🔍

Titan Biotech Ltd (524717)

📊 BSE: 524717 🏢 Specialty Chemicals 📢 Latest filing: 30 Sep 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Titan Biotech's revenue was ₹59.2 Cr (+27.2% year on year, +21.2% on the previous quarter), and net profit ₹10.9 Cr (+58.3% year on year); the operating margin was 21.1%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹59.2	+27.2%	+21.2%
Operating profit	₹12.5	+42.9%	+28.6%
Net profit	₹10.9	+58.3%	+61.3%
EPS (₹)	2.63	+58.4%	+61.3%
Operating margin	21.1%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Titan Biotech Increases Authorized Share Capital to Rs 10.40 Cr from Rs 10.00 Cr

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Sep 2026, 04:24 PM

Titan Biotech has amended its Memorandum of Association to increase its authorized share capital from Rs 10,00,00,000 to Rs 10,40,00,000. The alteration was approved by shareholders at the 34th Annual General Meeting held on September 29, 2026. This entails the creation of 20,00,000 new equity shares of face value Rs 2 each, taking total authorized shares to 5,20,00,000. The nominal addition of Rs 40 lakh in authorized capital is routine and creates headroom for future share issuances.

Authorized share capital increased from Rs 10,00,00,000 to Rs 10,40,00,000
Created 20,00,000 new equity shares of Rs 2 face value
Total authorized equity shares expanded from 5,00,00,000 to 5,20,00,000
Approval granted by shareholders at the 34th AGM on September 29, 2026

💡 Watch for subsequent corporate filings indicating why authorized capital was raised, such as potential employee stock options, preferential issues, or warrants.

Titan Biotech Sets Sep 22, 2026 Record Date for Dividend & Sep 29 for 34th AGM

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 12:32 PM

Titan Biotech Limited has scheduled its 34th Annual General Meeting (AGM) on September 29, 2026, via Video Conferencing/OAVM. The company fixed September 22, 2026, as the record date to determine shareholder entitlement for the FY26 final dividend. Register of members and book closure will run from September 23 to September 29, 2026. The remote e-voting period opens on September 26, 2026, and concludes on September 28, 2026.

34th AGM scheduled for September 29, 2026, at 3:00 PM IST via VC/OAVM
Record date fixed as September 22, 2026, for FY26 final dividend eligibility
Book closure from September 23, 2026, to September 29, 2026 (both days inclusive)
Remote e-voting window open from September 26, 2026 (10:00 AM) to September 28, 2026 (5:00 PM)

💡 Investors seeking final dividend eligibility should ensure shareholding prior to the September 22, 2026 record date; monitor voting results following the AGM on September 29, 2026.

Titan Biotech Board to Meet on Sep 3, 2026 to Consider Bonus Issue

🟢 POSITIVE ⭐ 4/10

BOARD_MEETING 📅 31 Aug 2026, 04:03 PM

Titan Biotech Ltd has scheduled a meeting of its Board of Directors on Thursday, September 03, 2026, to consider and approve a proposal for the issuance of bonus shares. The board will also finalize the notice and details for convening the 34th Annual General Meeting (AGM), along with book closure, record, and cut-off dates. In compliance with insider trading regulations, the trading window has been closed effective August 31, 2026, until 48 hours after the declaration of the board outcome.

Board meeting scheduled on September 03, 2026 to consider bonus issue
Meeting to finalize notice and dates for the 34th Annual General Meeting
Trading window closed from August 31, 2026 until 48 hours after board meeting results

💡 Track the outcome of the board meeting on September 03, 2026, for the proposed bonus share ratio and the subsequent record date.

Titan Biotech Q1 FY27: Consolidated PAT Surges 58% YoY to ₹10.86 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 03:55 PM

Titan Biotech reported a strong start to FY27 with consolidated revenue from operations reaching ₹59.17 Cr, a 27.2% increase over Q1 FY26. Net profit for the quarter surged 58.3% YoY to ₹10.86 Cr, significantly outperforming the ₹6.86 Cr reported in the same period last year. On a sequential basis, the performance was even stronger, with PAT growing 61.4% compared to Q4 FY26. The company's consolidated EPS improved to ₹2.63 from ₹1.83 YoY, reflecting robust operational efficiency.

Consolidated Revenue from operations grew 27.2% YoY to ₹59.17 Cr
Consolidated Net Profit increased 58.3% YoY to ₹10.86 Cr from ₹6.86 Cr
Consolidated EPS rose to ₹2.63 for the quarter, up from ₹1.83 in Q1 FY26
Profit Before Tax (PBT) stood at ₹12.73 Cr, a 57% increase over the ₹8.11 Cr reported in Q1 FY26
Total Income for the quarter reached ₹60.98 Cr, representing 28.8% of the total FY26 annual income

💡 Monitor the sustainability of these margins in upcoming quarters and watch for any management commentary regarding raw material cost trends, which impacted expenses by ₹29.93 Cr this quarter.

Titan Biotech Q1 Results: Consolidated PAT Jumps 58% YoY to ₹10.86 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 03:48 PM

Titan Biotech reported a strong start to FY27 with consolidated revenue growing 29.1% YoY to ₹60.98 Cr. Net profit for the quarter surged 58.3% YoY to ₹10.86 Cr, significantly outperforming the previous quarter's ₹6.73 Cr. Standalone operating margins showed notable improvement, reaching approximately 23.4% for the quarter compared to the TTM average of 18.7%. The company continues to operate with a very low debt-to-equity ratio of 0.03.

Consolidated Net Profit increased 58.3% YoY to ₹10.86 Cr from ₹6.86 Cr in June 2025
Total Income from operations grew 29.1% YoY to ₹60.98 Cr
Consolidated Basic EPS rose to ₹2.63 from ₹1.66 in the year-ago period
Standalone Profit Before Tax (PBT) stood at ₹12.73 Cr, a 57% increase over June 2025
Quarterly revenue of ₹60.98 Cr represents approximately 30% of the total TTM revenue of ₹206 Cr

💡 Investors should monitor the sustainability of the current 23%+ operating margins in upcoming quarters. Key focus should remain on whether this growth is driven by volume expansion or favorable raw material pricing in the specialty chemicals segment.

Titan Biotech Board Meeting on August 13, 2026, to Approve Q1 FY2027 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 05 Aug 2026, 11:34 AM

Titan Biotech Ltd has scheduled a board meeting for August 13, 2026, to consider and approve its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. This is a routine regulatory filing following the close of the first quarter of the 2026-27 fiscal year. The company reported a TTM revenue of ₹206 Cr and a PAT of ₹30 Cr for FY26. The trading window for designated persons has been closed since July 1, 2026, and will reopen 48 hours after the results are declared.

Board meeting scheduled for August 13, 2026, to approve Q1 results.
Financial results pertain to the quarter ended June 30, 2026.
Trading window closure initiated on July 1, 2026, as per SEBI regulations.
Company reported a TTM OPM of 18.7% and ROCE of 23.0% leading into this quarter.

💡 Monitor the official results release on August 13, 2026, to evaluate if the company maintains its growth momentum and operating margins (18.7% TTM).

View All 524717 Announcements on Live Market Tracking →